In the present study, we found that Cav-1 expression was more frequently observed in tumor cells of metastatic lymph nodes than of primary sites and that high metastatic tumoral Cav-1 expression was associated with poor clinical outcome in the patients with resected GC, not primary tumoral or stromal Cav-1 expression. This evidence concerns the gene CAV1 and gastric cancer.